Neurological sequelae of cancer immunotherapies and targeted therapies
The DOI matches its Crossref record; 73 of the 75 references it cites were found in a registry or an index.
Abstract
Neurological complications of cancer and of anticancer treatments can be substantially disabling to patients, especially with classic chemotherapies. As a rare but important complication, targeted therapies might also result in similar unwanted effects, partly because inhibition of VEGF is a common downstream effect. Therapeutic antibodies, such as the CD20-depleting antibody rituximab, and underlying haematological malignancies, can induce long-lasting cellular immunosuppression, predisposing patients to opportunistic CNS infections, such as progressive multifocal leukoencephalopathy, where treatment-induced recovery can result in severe reconstitution of immune inflammatory syndromes of the central nervous system. Immune-related neurological adverse events, particularly from immune-activating checkpoint inhibitors, occur as a result of immune activation, resulting in organ-specific autoimmune-like disease. The prevalence of immune-related neurological adverse events might only be about 1%-a low prevalence compared with toxicities in other organs-but it constitutes new patterns of neurological toxic forms, which could result in considerable morbidity and fatal outcomes. Clinicians should be aware of treatment-associated neurotoxicity, and consider discontinuation of the drug with parallel supportive measures to help patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most severe of these immune-related adverse events (irAEs) are cytokine release syndrome (CRS) and neurotoxicity, most prominently described in patients treated with CAR-T-cells [6–11].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [9]
In the citing paper
“although headache is now a well-described irAE [9].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [9]
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Research works printed but not linked: 1
- Dirix, 2010, Arterial hypertension induced by vascular endothelial growth factor interfering agents: mechanisms and management, Belg J Med Oncol, 4, 159
Cited by
Depression and anxiety in patients with cancer
Pitman, A., Suleman, S., Hyde, N., & Hodgkiss, A. (2018) · BMJ · doi:10.1136/bmj.k1415 · Cited by 871
Jordan, B., Margulies, A., Cardoso, F., Cavaletti, G., Haugnes, H. S., Jahn, P., Le Rhun, E., Preusser, M., Scotté, F., Taphoorn, M. J. B., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.003 · Cited by 338
Wojtukiewicz, M. Z., Rek, M. M., Karpowicz, K., Górska, M., Polityńska, B., Wojtukiewicz, A. M., Moniuszko, M., Radziwon, P., Tucker, S. C., & Honn, K. V. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09976-0 · Cited by 335
Mikulska, M., Lanini, S., Gudiol, C., Drgona, L., Ippolito, G., Fernández-Ruiz, M., & Salzberger, B. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.003 · Cited by 205
Dalakas, M. C. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418799864 · Cited by 176
Metadata
- Authors
- Wick, W., Hertenstein, A., & Platten, M.
- Affiliations
- German Cancer Research Center (DE)
- Corresponding author
- Wick, Wolfgang
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 17
- Issue
- 12
- Pages
- e529-e541
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2557614618
- Cited by
- 87
- References
- 75
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 13 · 2020: 17 · 2019: 12 · 2018: 13 · 2017: 7
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim
- Pfizer
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Clinical Neurology › Autoimmune Neurological Disorders and Treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- cancer immunotherapy, targeted therapy, VEGF inhibition, rituximab, progressive multifocal leukoencephalopathy, opportunistic CNS infection, immune checkpoint inhibitors, immune-related adverse events, chemotherapy-induced neurotoxicity, hematologic malignancies
- MeSH terms
- Brain Diseases, Cerebellar Diseases, Humans, Immunotherapy, Neoplasms, Nervous System Diseases, Seizures, Leukoencephalopathies, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurological sequelae of cancer immunotherapies and targeted therapies. https://app.cochat.ai/papers/10.1016/s1470-2045(16)30571-x
- The paper
- Wick, W., Hertenstein, A., & Platten, M. (2016). Neurological sequelae of cancer immunotherapies and targeted therapies. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(16)30571-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.